Milan Kvapil s.r.o.

Milan Kvapil s.r.o. conducts research targeting cardiovascular diseases, aiming to improve outcomes for patients at risk of heart attacks, strokes, and related vascular events.

• Atherosclerotic cardiovascular disease – studying therapies to slow plaque buildup.
• Established cardiovascular disease – evaluating treatments to reduce recurrent events.
• High cardiovascular risk – testing interventions to prevent first events.
• Hypertension – assessing novel agents for better blood pressure control.
• Chronic kidney disease – investigating kidney‑protective strategies linked to heart health.

Current trials compare new agents such as vicadrostat combined with empagliflozin, AZD0780, and zilebesiran against placebo to determine their impact on major adverse cardiovascular events, renal function, and hospitalization for heart failure.

The center also specializes in nutritional and metabolic diseases, focusing on obesity and weight management in the context of diabetes and metabolic health.

• Chronic weight management – testing the efficacy of maridebart cafraglutide for sustained weight loss.
• Type 2 diabetes with obesity – evaluating how weight reduction influences glycemic control.
• Metabolic risk reduction – exploring the broader impact of weight loss on cardiovascular risk factors.

These studies aim to demonstrate that the investigational drug can achieve greater percent body‑weight change compared with placebo, potentially offering a new therapeutic option for patients struggling with obesity.